key: cord-0894821-hxzi333g
authors: Reddy, Nalla Anuraag; Tom, Alex; Lashkari, Harsha Prasada
title: Acute myeloid leukemia complicated by post COVID-19 multi-system inflammatory syndrome-children
date: 2021-12-21
journal: Pediatric Hematology Oncology Journal
DOI: 10.1016/j.phoj.2021.12.004
sha: 09af2088d9ac4bd7e20fa434ffbbc2fefc2e019d
doc_id: 894821
cord_uid: hxzi333g

Corona Virus disease 2019 (COVID-19) pandemic has presented a huge challenge to the health care system in terms of magnitude of cases and to pediatric oncology units with varied clinical presentations. Acute myeloid leukemia(AML) is a rare heterogenous cancer of childhood with an induction mortality around 15% in our country due to neutropenic sepsis. Multisystem inflammatory syndrome in children(MIS-C) is an hyperinflammatory syndrome seen 4–6 weeks after COVID-19 infection. COVID infection in some of these children would have gone unnoticed. Here we report a two year eight months old boy diagnosed with AML on induction chemotherapy developed post COVID MIS-C.

Acute myeloid leukemia (AML) is a rare childhood disease with an incidence of 7 cases per a million children younger than 15 years, accounting for 15-30% of childhood leukemias. It has a survival rate of 70% which has improved owing to intensive chemotherapy regimens and improved supportive care [1, 2] .The average induction mortality in AML in developing countries like India is around 15%. The common cause for mortality is gram negative bacterial infection or fungal infection [3] . Severe acute respiratory distress syndrome Corona virus 2 (SARS-CoV2) pandemic has challenged the health care system throughout the world not only by its sheer magnitude of numbers but also in its diverse ways of presentation [4] . COVID-19 predominantly presents with respiratory involvement with varied degrees of severity. Severe respiratory involvement is relatively less common in children as compared to adults [5] . Multisystem J o u r n a l P r e -p r o o f inflammatory syndrome in children (MIS-C) is a hyperinflammatory syndrome occurring post corona virus infection presenting with multisystem features like Kawasaki disease or toxic shock syndrome 4-6 weeks following COVID infection [6] . Here we discuss a child with AML on induction chemotherapy who developed very high-grade fever spikes which later was diagnosed as post COVID MIS-C. There was no history of exposure or infection with COVID-19 before. He was given intravenous immunoglobulin(IVIg) 2g/kg as he continued to have fever. His COVID Ig-G titers, serum ferritin, lactate dehydrogenase (LDH), C-reactive protein (CRP), interleukin-6 (IL-6) were sent for testing. However, as he continued to have high fever spikes, 12 hours after IVIg, the child was started on high dose dexamethasone 10mg/m2/day in two divided doses. The reports showed J o u r n a l P r e -p r o o f ferritin of 2600 ng/ml(7-140ng/ml), IL 216 (0-7 pg/ml), CRP -52 mg/L(<5mg/L), LDH 320 U/L, albumin 2.5 g/dl, COVID IgG antibody titre 17 (<1 is non-reactive). The child became apyrexial within 6 hours of starting steroids and it was continued for 2 more days(figure 1). The child developed erythematous maculopapular rash all over his body further. Two-dimensional echocardiogram didn't reveal any coronary artery dilatation but showed mild serous effusion.

His CSF flow-cytometry was negative for malignancy. He successfully completed his 2 courses of induction and has just completed the two courses of high dose cytarabine consolidation.

Febrile neutropenia is an oncological emergency, more so during induction phase of AML chemotherapy. Prompt initiation of antibiotic therapy after sending appropriate cultures is of paramount importance in its management [8] . MIS-C is a novel clinical entity with a clinical overlap with Kawasaki disease, Toxic shock syndrome. WHO diagnostic criteria incorporate a wide range of symptoms from cardiac abnormalities to gastrointestinal symptoms. It is associated with elevated inflammatory parameters like ferritin, lactate dehydrogenase, interleukin-6, C-reactive protein [ Table 1 ] [6] .

Our patient presented with febrile neutropenia on day 8 of induction and he was started on appropriate antibiotic therapy. It is very common to have gram negative sepsis or fungal blood stream infection leading to persistent fever spikes during induction. Starting high dose dexamethasone during severe neutropenia is a difficult decision, but in our patient due to nonsubsidence of fever an inflammatory etiology was suspected with post COVID MIS-C being our J o u r n a l P r e -p r o o f first differential owing to the epidemiological and temporal association with the SARS-CoV2 pandemic. The biochemical parameters were also supportive of our diagnosis of MIS-C.

Though there was no history of COVID in this child or his family 4 weeks ago, he did have fever and myalgia which the family and we thought were part of his AML symptoms. During this current pandemic any unusual presentation or unexplained fever one needs to be highly suspicious of MIS-C [9] . Even though there is no confirmatory test for MIS-C, the clinical picture, biochemical parameters, and response to steroids make post-COVID MIS-C a likely diagnosis.

Hiwarkar et al reported a case of refractory Acute myelomonocytic leukemia M5 referred for transplant who presented with fever, gastrointestinal symptoms and cardiac manifestations. Their patient responded to high dose steroids [10] . Immune disequilibrium due to underlying leukemia and intense chemotherapy would be responsible for manifestations of such hyperinflammatory syndrome. High index of suspicion is needed in such cases as immunosuppressive therapy can be lifesaving. 

AML Committee of the International BFM Study Group. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel

From Biology to Clinical Management

Induction Related Mortality in Acute Myeloid Leukemia: Multivariate Model of Predictive Score from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey

The Wide Spectrum of COVID-19 Clinical Presentation in Children

Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation

The World Health Organization (WHO) classification of the myeloid neoplasms

Febrile neutropenia in paediatric oncology

Unusual Clinical Manifestations and Outcome of Multisystem Inflammatory Syndrome in Children (MIS-C) in a Tertiary Care Hospital of North India

SARS-CoV-2-related multisystem inflammatory syndrome in an immunocompromised child with leukemia